Merck gets dueling analyst calls after vaccine data rally
Merck draws mixed analyst action after promising cancer vaccine results lifted shares almost 13% yesterday, with RBC Capital Markets downgrading to hold and Morgan Stanley upgrading to buy.
MRK Dueling calls on Merck after yesterday's promising cancer vaccine results sent shares up almost 13%.
RBC Capital Markets downgraded the drugmaker to hold from buy, saying risk/reward for the stock is now fairly valued.
Morgan Stanley went the other way, upgrading to buy from hold on a belief Merck can better navigate the looming Keytruda patent Cliff.
Merck shares were down modestly this morning. - per Cramer Investing Club Newsletter